ClinicalTrials.gg
Not yet recruitingNCT06664320Updated Oct 31, 2024

Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery

An interventional study of Acute normovolemic hemodilution (ANH) and hydroxyethyl starch (HES 130/0.6) in Mitral Regurgitation, Mitral Stenosis and Tricuspid Regurgitation, sponsored by Konkuk University Medical Center. Not yet recruiting at 2 sites in Korea, Republic of. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Konkuk University Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Mitral Valve Insufficiency · Korea, Republic of.

Started
2024
with 1 other
No phase
2 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
4 of 11
Konkuk University Medical Center

Among the 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of, this one is one of 2 that started in 2024, is one of 2 with no phase, and was the 9th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

3 of the 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 19 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Mitral Valve Insufficiency with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Patients undergoing cardiac surgery employing moderate hypothermic CPB are randomly allocated into one of two groups: in Group-ANH, ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied. After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM, and APTEM profiles are analyzed. As a primary outcome, the inter-group differences between maximal clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.

Read the detailed description

Background: The impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Method: Patients undergoing cardiac surgery employing moderate hypothermic CPB are randomly allocated into one of two groups: in Group-ANH(n=29), ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C ANH (n=29)is not applied. Intergroup differences of INTEM, EXTEM, FIBTEM, and APTEM profiles are analyzed. after anesthesia induction (control) and after weaning from CPB and protamine neutralization (after-CPB) in both groups. In Group-ANH, those are determined after ANH (after-ANH). As a primary outcome, the inter-group difference between maximal clot firmness of EXTEM is determined at 10 min after ANH in Group-ANH and that at control. As secondary outcomes, intergroup differences of Hematocrit (Hct), Na+, K+, HCO3-, Ca2+, osmolarity, and s-Cr are determined Intergroup differences of data at T2 are performed.

03

Conditions studied

  • Mitral Regurgitation
  • Mitral Stenosis
  • Tricuspid Regurgitation

Keywords

  • rotational thromboelastometry
  • cardiac surgery
  • acute normovolemic hemodilution
  • hemodilution
  • coagulation
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients undergoing cardiac surgery with cardiopulmonary bypass who signed written

Exclusion criteria

Exclusion Criteria:

  • preoperative renal failure requiring reran replacement therapy
  • preoperative liver disease
  • preoperative low cardiac output (EF \< 50%)
  • Preoperative IABP application, Atrial fibrillation, Pacemaker
  • for applying TEE
  • intraoperative withdrawal
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • No intervention
    Control group

    patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB

  • Active comparator
    Acute normovolemic hemodilution group

    patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB

    Procedure: Acute normovolemic hemodilution (ANH) · Drug: hydroxyethyl starch (HES 130/0.6)

Interventions

  • ProcedureAcute normovolemic hemodilution (ANH)

    applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass

  • Drughydroxyethyl starch (HES 130/0.6)

    Drug page: Hydroxyethyl Starch DerivativesStudies of Hydroxyethyl Starch DerivativesHydroxyethyl Starch Derivatives pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    hydroxyethyl starch (HES 130/0.6)

06

What researchers measure

Primary outcomes

  1. Maximal clot firmness of EXTEM

    Maxiaml clot firmess (MCF) of EXTEM of rotational thromboleastometry

    Time frame: 10 min after completion of acute normovolemic hemodilution (ANH)

Secondary outcomes

  1. Clot formation time of EXTEM

    Clot formation time of EXTEM of rotational thromboleastometry

    Time frame: 10 min after completion of acute normovolemic hemodilution

  2. A10 of FIBTEM

    A10 of FIBTEM of rotational thromboelastometry

    Time frame: 10 min after completion of acute normovolemic hemodilution

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Mar 2025, 5 months later.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2024
First posted
Oct 29, 2024
StartEst.
Oct 28, 2024
Primary completionEst.
Mar 30, 2025
CompletionEst.
Apr 30, 2025
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06664320
Lead sponsor
Konkuk University Medical Center
Responsible party
Tae-Yop Kim, MD PhD (Professor of Anesthesiology, Konkuk University Medical Center) — Principal investigator
First posted
Oct 29, 2024
Start date
Oct 28, 2024 (estimated)
Primary completion
Mar 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Oct 31, 2024

Study contacts

Tae-Yop Kim, MD, PhD
Contact
taeyop@gmail.com
+82-2-2030-5445
Wooseul Lee, Bachelor
Contact
wslee.kku@gmail.com
+82-2-2030-5448
Tae-Yop Kim, MD, PhD
principal investigator · Konkuk University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxyethyl Starch Derivatives

Start the discussion